Martin-Padura et al. [67] revealed that CD13+ cells were in minimal residual disease (MRD) via orthotopic HCC mouse models by injection of human AFP and/or luciferase-expressing HCC cell lines and primary HCC cells, and this also suggested that targeting dormant CSCs was critical for treatment success. The gene discussed is ANPEP; the disease is hepatocellular carcinoma.